Form 8-K ROCKET PHARMACEUTICALS, For: May 27
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Wall Street ends sharply higher as Waller remarks ease rate hike fears
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
JPMorgan Downgrades Rocket Pharmaceuticals (RCKT) to Neutral
May 28, 2025 3:07 PM EDTJPMorgan analyst Eric Joseph downgraded Rocket Pharmaceuticals (NASDAQ: RCKT) from Overweight to Neutral with a price target of $7.00 (from $44.00).
The analyst comments "We are downgrading RCKT shares to Neutral from Overweight on the back of yesterdays announced clinical hold on lead program RP-A501... More
Goldman Sachs Downgrades Rocket Pharmaceuticals (RCKT) to Sell
May 28, 2025 9:35 AM EDTGoldman Sachs analyst Richard Law downgraded Rocket Pharmaceuticals (NASDAQ: RCKT) from Buy to Sell with a price target of $2.00 (from $13.00).
The analyst comments "On Tuesday (5/27), RCKT announced that the FDA placed a clinical hold on its pivotal Ph. 2 Danon disease (DD) trial. The hold was issued on 5/23 after a patient treated in early May experienced capillary... More
Rocket Pharmaceuticals (RCKT) PT Lowered to $9 at BofA Securities
May 28, 2025 5:13 AM EDTBofA Securities analyst Greg Harrison lowered the price target on Rocket Pharmaceuticals (NASDAQ: RCKT) to $9.00 (from $32.00) while maintaining a Buy rating.
The analyst comments "Rockets announcement of a death in its RP-A501 phase 2 for rare disorder Danon is tragic on... More
William Blair Reiterates Outperform Rating on Rocket Pharmaceuticals (RCKT)
May 27, 2025 10:49 AM EDTWilliam Blair analyst Sami Corwin reiterated an Outperform rating on Rocket Pharmaceuticals (NASDAQ: RCKT).
The analyst comments "Stock Thoughts: We view the patient death and subsequent clinical hold as unfortunate; however, we believe the pausing of dosing is necessary given CLS is a safety event not previously observed with RP-A501 or other AAV gene therapies, to our knowledge. While we cannot fully eliminate the possibility that... More
BMO Capital on Rocket Pharmaceuticals (RCKT): 'we expect today's announcement...to significantly pressure RCKT'
May 27, 2025 8:10 AM EDTBMO Capital analyst Kostas Biliouris reiterated an Outperform rating and $30.00 price target on Rocket Pharmaceuticals (NASDAQ: RCKT).
The analyst comments "Mgt announced a patient death in Danon trial following capillary leak syndrome sAE, triggering a clinical hold by the FDA. Importantly, the event... More
Jefferies on Rocket Pharmaceuticals (RCKT): 'We expect significant stock weakness'
May 27, 2025 8:07 AM EDTJefferies analyst Andrew Tsai reiterated a Buy rating and $29.00 price target on Rocket Pharmaceuticals (NASDAQ: RCKT).
The analyst comments "We expect significant stock weakness as a Danon patient died due to an acute systemic infection (following an SAE), leading the... More
Morgan Stanley on Rocket Pharmaceuticals (RCKT): 'we expect RCKT shares to be under significant pressure today'
May 27, 2025 8:05 AM EDTMorgan Stanley analyst Michael E Ulz reiterated an Overweight rating and $42.00 price target on Rocket Pharmaceuticals (NASDAQ: RCKT).
The analyst comments "Ph2 pivotal Danon study on clinical hold due to SAE and subsequent patient death. Rocket announced (PR here) that it had voluntarily paused dosing in its Ph2 study of RP-A501, its AAV9-based gene therapy for the... More
